Effect of Bosentan on Endothelial Function in Patients With Type 2 Diabetes

Phase 2 Completed 56 enrolled Karolinska Institutet Actelion · collab Swedish Heart Lung Foundation · collab The Swedish Research Council · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to investigate if oral treatment with bosentan improves endothelium-dependent vasodilatation in patients with type 2 diabetes and microangiopathy.

Timeline

Start: 2007-11
Primary completion: 2010-04
Completion: 2011-01

Outcome

Met primary endpoint

paper The change in reactive hyperaemia index from baseline was greater in the bosentan group than in the placebo group (p < 0.05). PMID 22200728 ↗

Publications

Rafnsson A, Bohm F, Settergren M, Gonon A, Brismar K, Pernow J. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia. 2012 Mar;55(3):600-7. doi: 10.1007/s00125-011-2415-y. Epub 2011 Dec 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bosentan	Other / unclassified	125 mg	—